Tabimorelin dosing & administration
An investigational oral growth hormone secretagogue that stimulates GH release through ghrelin receptor activation, though development was discontinued due to drug interaction concerns.
Written by Michael Carroll — Owner, Director of Research · Reviewed by the Peptide Initiative Research Team · Editorial standards
Dosing
How much do I take?
Oral: Taken by mouth as a capsule, tablet, or liquid.
Bioavailability Varies by compound — many peptides are largely broken down in the gut, so little reaches the blood intact; some small molecules absorb well.
Timing
Best time to take
Evening or before bedtime (mirrors natural GH secretion patterns)
With food?
Take Tabimorelin on an empty stomach for optimal absorption, or with a light meal if GI discomfort occurs. Avoid heavy meals within 30 minutes of dosing.
If stacking
If combining Tabimorelin with other peptides or supplements, space administrations by at least 15-30 minutes when possible. Consult with a healthcare provider before combining with prescription medications.
Adjusting your dose
Increase if
- You've tolerated the current dose for the recommended period without significant side effects
- Therapeutic goals haven't been met at the current dose level
- Your healthcare provider recommends dose escalation based on your response
- Lab work or clinical assessments support a higher dose
Decrease if
- Side effects are bothersome or impacting daily life despite management strategies
- You experience any signs of an adverse reaction
- Lab results indicate the need for dose reduction
- Your healthcare provider recommends a lower dose based on your response
Signs of right dose
- Therapeutic goals being met with minimal side effects
- Stable and consistent response to treatment
- Lab values or clinical markers trending in the right direction
- Good tolerance with manageable or absent side effects
Administration
How do I use it?
Reconstitution
What you need
Injection
Route
Not applicable — oral formulation only
Best sites
Storage
Before reconstitution
Store Tabimorelin in the refrigerator at 36-46°F (2-8°C) in its original packaging. Protect from light and moisture. Do not freeze. Check the expiration date before use. Some formulations may be stored at room temperature for limited periods—check your specific product labeling.
After reconstitution
Once reconstituted, Tabimorelin should be kept refrigerated at 36-46°F (2-8°C) and used within the timeframe specified on your product labeling (typically 14-28 days). Label the vial with the reconstitution date. Do not use if the solution appears cloudy, discolored, or contains particles.
Signs of degradation — discard the vial
Safety
Is it safe?
Side effects
Commonly reported: Headache, Nausea, Appetite stimulation, Dizziness, Dry mouth
Stop and seek help if
- Severe or worsening side effects that don't improve with dose adjustment or supportive care
- Signs of an allergic reaction—rash, hives, swelling, or difficulty breathing
- Your healthcare provider recommends discontinuation based on your clinical response
- Development of any new medical condition that may be contraindicated with Tabimorelin
- Pregnancy or planning to become pregnant (unless specifically approved for use during pregnancy)
- Abnormal lab results or clinical markers that suggest adverse effects
Tabimorelin should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.
Flagged pairings
- Strong CYP3A4 inhibitors (itraconazole, ritonavir, clarithromycin) — tabimorelin itself inhibits CYP3A4, creating bidirectional interaction risks — Use with caution—discuss with your healthcare provider.
- CYP3A4 substrates (statins, certain antiarrhythmics, immunosuppressants) without careful monitoring — Use with caution—discuss with your healthcare provider.
Published research
What the studies show
Zdravkovic M, et al. · 2000
This study investigated the properties and effects of Tabimorelin, contributing to our understanding of its mechanism of action and potential therapeutic applications.
Svensson J, et al. · 2003
This study investigated the properties and effects of Tabimorelin, contributing to our understanding of its mechanism of action and potential therapeutic applications.
Agersø H, et al. · 2001
This study investigated the properties and effects of Tabimorelin, contributing to our understanding of its mechanism of action and potential therapeutic applications.
Head to head
Tabimorelin compared
Want the full picture?
The complete Tabimorelin research profile: mechanism of action, clinical studies, effectiveness timeline, and FAQ.